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Purpose. Using the classical Ankaferd Blood Stopper (ABS) solution to create active hemostasis during partial nephrectomy
(PN) may not be so effective due to insufficient contact surface between the ABS hemostatic liquid agent and the bleeding area.
In order to broaden the contact surface, we generated a chimeric hemostatic agent, ABS nanohemostat, via combining a self-
assembling peptide amphiphile molecule with the traditional Ankaferd hemostat.Materials andMethods. In order to generate ABS
nanohemostat, a positively charged Peptide Amphiphile (PA) molecule was synthesized by using solid phase peptide synthesis. For
animal experiments, 24Wistar rats were divided into the following 4 groups: Group 1: control; Group 2: conventional PN with only
0.5ml Ankaferd hemostat; Group 3: conventional PN with ABS + peptide gel; Group 4: conventional PN with only 0.5ml peptide
solution. Results. Mean warm ischemia times (WITs) were 232.8 ± 56.3, 65.6± 11.4, 75.5± 17.2, and 58.1± 17.6 seconds in Group 1
to Group 4, respectively. Fibrosis was not different among the groups, while inflammation was detected to be significantly different
in G3 and G4. Conclusions. ABS nanohemostat has comparable hemostatic efficacy to the traditional Ankaferd hemostat in the
partial nephrectomy experimental model. Elucidation of the cellular and tissue effects of this chimeric compound may establish a
catalytic spark and open new avenues for novel experimental and clinical studies in the battlefield of hemostasis.
1. Introduction
The use of nanomaterials in medicine involves the applica-
tions of nanoparticles andmanufactured nanosystems to pro-
vide regeneration at the cellular and tissue levels [1]. Several
nanomaterials have been designed to serve as drug delivery
systems. They encapsulate therapeutic agents and typically
carry multiple targeting motifs such as hemostasis [1, 2].
For instance, Ellis-Behnke and coworkers [2] introduced
a unique nanomedicinal method to stop bleeding using a
self-assembling peptide that establishes a nanofiber barrier
and incorporates it into the surrounding tissue to form an
extracellular matrix [1, 2].
Biomaterials used as tissue engineering scaffolds have
specific physical properties and might form fibrous networks
similar to collagenous extracellular matrix. They also can be
programmed to carry chemical and physical cues to provide
bioactivity for cell-materials interactions. In the search for
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more improved bioactive materials for tissue engineering
purposes, peptide amphiphile (PA) molecules are good can-
didates to bring scaffold properties and bioactivity together
[3, 4]. Hydrophobic region of the PA is composed of fatty
acids, which are packed against aqueous medium inducing
self-assembly of the molecule to form cylindrical nanofibers.
Charged amino acids on hydrophilic peptide region of the PA
molecules are responsible for triggering self-assembly upon
isolation of charges [5]. Neutralization of charge density on
amino acids causes aggregation of PA molecules and forma-
tion of nanofibrous networks at microscale. Encapsulation of
water by these nanofiber networks results in constitution of
self-supporting gel at macroscale [6]. Peptide part of the PA
molecules can be synthesized in a way to include bioactive
epitopes or biofunctional chemical groups, which are even-
tually presented to cells on nanofibers. PA gels carrying these
types of functionalities have been studied thoroughly and
proven to be active in terms of inducing angiogenesis, neu-
ronal regeneration, and cartilage and bone tissue formation
[7–10]. Charge neutralization mechanism also allows us to
use bioactive molecules with high negative or positive charge
density, such as heparin, DNA, or oligonucleotides for induc-
ing gel formation, while exploiting their bioactivity [6, 11, 12].
The use of medicinal plants as remedies for numerous
disorders has formed the basis of currentmedicinal approach.
Various plants are used ethnomedicinally for prevention of
excessive bleeding and as wound dressing to staunch blood
flow [13]. Ankaferd hemostat, a topical hemostatic agent of
plant origin, has recently been registered for themanagement
of clinical hemorrhages when the conventional methods to
control bleeding by ligature and/or hemostatic measures are
ineffective [14–16]. Ankaferd Blood stopper (ABS) includes
standardized preparation of the plants Thymus vulgaris,
Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum, and
Urtica dioica [17, 18].
ABS provides vital erythroid aggregation covering the
entire physiological hemostatic process via a unique protein
network depending primarily on the interactions between
ABS and blood proteins, particularly with fibrinogen gamma
and prothrombin [16, 19–22]. Vital erythroid aggregation
takes place with the spectrin and ankyrin receptors on the
surface of red blood cells (RBCs). Those RBC proteins and
the required ATP bioenergy are included in the ABS protein
library [23, 24]. On the other hand, controlled clinical trials
indicated the safety and efficacy of topical Ankaferd hemostat
in distinct clinical backgrounds [19, 25–31].
In this work, we present a chimeric hemostatic agent, ABS
Nanohemostat, via combining a self-assembling PAmolecule
with the traditional Ankaferd hemostat. The first step of our
research was the synthesis of the specific self-assembling
peptide molecules capable of being a part of the combined
ABS Nanohemostat compound. The second step was the
assembly of the peptide nanofibers and ABS to generate
the ABS Nanohemostat. The third step of our study was
testing the in vivo hemostatic effects of ABS Nanohemostat
in comparison with the traditional Ankaferd in a previously
established and published controlled surgical experimental
trial in kidney tissue [32]. The ultimate aim of the present
study is, therefore, to test the efficacy of ABS Nanohemostat
formed by combination of a self-assembling PAmolecule and
Ankaferd hemostat for controlling surgical bleeding due to
renal injury during partial nephrectomy (PN) and to compare
its hemostatic effects to the traditional surgical and Ankaferd
hemostat groups.
2. Materials and Methods
2.1. Nanomedicinal Approach and ABS Nanohemostat
2.1.1. Materials. 9-Fluorenylmethoxycarbonyl (Fmoc), ter.
Butoxycarbonyl (Boc) protected amino acids, Rink Amide
MBHA resin, and 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetrameth-
yluronium hexafluorophosphate (HBTU) were purchased
fromNovaBiochem or ABCR.The other chemicals were pur-
chased from Fisher, Merck, Alfa Aesar, or Aldrich and used
as provided.
2.1.2. Peptide Synthesis. Peptides were constructed on Rink
Amide MBHA resin. Amino acid couplings were done with
2 equivalents of Fmoc protected amino acid, 1.95 equiva-
lents HBTU, and 3 equivalents of N,N-diisopropylethylamine
(DIEA) for 2 hours. Fmoc removal was performed with 20%
Piperidine/Dimethylformamide (DMF) solution for 20min.
Cleavage of the peptides from the resin was carried out
with a mixture of TFA : TIS : H
2
O in ratio of 95 : 2.5 : 2.5
for 2 h. Excess TFA was removed by rotary evaporation.
The remaining viscous peptide solution was triturated with
ice-cold ether, and the resulting white product was dried
under vacuum. PA molecules were characterized by liq-
uid chromatography-mass spectrometry (LC-MS) (Figure 1).
Mass spectrum was obtained with Agilent LC-MS equipped
with Agilent Zorbax Extend-C18 2.1 × 50mm column. A
gradient of (a) water (0.1% formic acid) and (b) acetonitrile
(0.1% formic acid) was used.
2.1.3. Peptide Amphiphile Molecule Design. The PA was syn-
thesized by Fmoc Solid Phase Peptide Synthesis (SPPS)
method. It is composed of a lauryl (C12) group, hydrophobic
region of the PA, and a peptide sequence. VVAG peptide
sequence is used as 𝛽-sheet inducer that causes nanofiber
formation, while the lysine (K) residue is protonated at
physiological pH and increases solvation of PA molecule in
aqueous solution at pH 7. Figure 2 shows both the chemical
structure of the PA (Lauryl-VVAGK-Am) and the schematic
representation and ABS Nanohemostat formation.
2.1.4. Circular Dichroism (CD). JASCO J815 CD spectropo-
larimeter was used at room temperature. 1 × 10−4M peptide
solutions were measured from 300 nm to 190 nm, data inter-
val and data pitch being 0.1 nm and scanning speed being
100 nm/min, all measurements with three accumulations.
Digital integration time (DIT) was selected as 1 sec, band
width as 1 nm, and the sensitivity was standard.
2.1.5. Rheology. Oscillatory rheology measurements were
performedwith Anton Paar Physica RM301 Rheometer oper-
ating with a 25mm parallel plate configuration at 25∘C. Each
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Figure 2: Schematic representation of ABS Nanohemostat formation by self-assembly of peptide amphiphile molecules into nanofibers upon
addition of Ankaferd solution.
sample of 100 𝜇L total volume with a final peptide concen-
tration of 1 wt% was carefully loaded on the center of the
lower plate and incubated for 15min before measuring. After
equilibration, the upper plate was lowered to a gap distance
of 0.5 mm. Storage moduli (G󸀠) and loss moduli (G󸀠󸀠) values
were scanned from 100 rad/s to 0.1 rad/s of angular frequency,
with a 0.5% shear strain.
2.1.6. Scanning Electron Microscopy (SEM) Imaging. SEM
experiments were performed with FEI Nova NanoSEM 230,
using the ETD detector at low vacuum mode with 30 keV
beam energy. Small amounts of gels with a final peptide
concentration of 1%were put on ametalmesh, dried at critical
point (1072 Psi, 31∘C) with Tousimis Autosamdri-815 B Series
C critical point dryer and coated with 6 nm Au-Pd. Figure 3
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Figure 3: Scanning Electron Microscopy images of peptide amphiphile (PA) gel with Ankaferd (a) or alone (b) at pH 10.
shows SEM images of PA gel with and without Ankaferd at
pH 10.
2.1.7. In Vivo Application of PA and Ankaferd Gel. An amount
of 250𝜇L of PA was mixed with 250𝜇L ABS solution on
glass slide and incubated at room temperature for 30min for
self-supporting gel formation. Due to anionic molecules in
Ankaferd solution, self-supporting gel was formed immedi-
ately after mixing. This gel was applied directly onto wound
area.
2.2. Surgical Approach and ABS Nanohemostat
2.2.1. Animals. All animal experimentations described in
this paper were carried out in accordance with national
guidelines for the use and care of laboratory animals andwere
approved by the local animal review and ethics committee.
All procedures were in full compliance with Turkish Law
6343/2, Veterinary Medicine Deontology Regulation 6.7.26,
and with the Helsinki Declaration of World Medical Associ-
ation recommendations on animal studies. The animals were
obtained from the center of medical experimental research of
Ankara Training andResearchHospital.The ratswere housed
in stainless steel cages in an animal room maintained at a
temperature of 22–24∘C with 12-hour light/dark periods. All
were fed with the same amount of laboratory pellet diet and
withwater supplied ad libitum for aminimumof 5 days before
procedure.
2.2.2. Rat Model of Partial Nephrectomy. A total of 24 Wistar
rats weighing 200 to 300 g were divided into 4 groups of
6 each and underwent PN. One surgeon with an assistant
performed all the surgical procedures. All operations were
performed under total anesthesia with injection of 50mg/kg
intramuscular ketamine hydrochloride. After sterile prepa-
ration and draping, a midline incision was made on the
abdomen. For each rat, renal artery and vein were revealed
by hilar vascular dissection. Subsequently, renal artery and
vein were clamped with Rommel vascular clamp. The lower
third of the left kidney was resected in guillotine fashion
with a single stroke of an amputating knife. Four different
hemostatic techniques were applied to the groups.
(i) Group 1 (G1) is the left PN with hilar vascular
control including intracorporeal suturing of the renal
parenchyma and collecting duct (control group).
(ii) Group 2 (G2) is the conventional PN with only
0.5mL traditional Ankaferd hemostat (ABS) applica-
tion without suturing.
(iii) Group 3 (G3) is the conventional PN with ABS
(0.25mL) + peptide (0.25mL) gel (ABS Nanohemo-
stat) mixture application with no suturing.
(iv) Group 4 (G4) is the conventional PN with only
0.5mL peptide solution application.
Two objective parameters were recorded during the
surgical procedure: warm ischemia time (WIT) and amount
of bleeding (AOB). The unit of WIT was the “second,” while
the AOB was measured with the bleeding area (cm2) onto
the sponges. The abdominal incision was afterwards closed
with surgical sutures. All the rats were allowed to feed and
drink water for the following 4 weeks. After that, each rat
was sacrificed, and total nephrectomy was performed for
histopathological examination.
2.2.3. The Hemostatic Methods during PN. Each hemostatic
method was used during the period of warm ischemia
(WI). WI started with clamping the renal artery and vein
and finished with taking the clamp out. In G1, traditional
hemostasis method was used as compression onto the renal
excised area and suturing the renal vessels and collecting duct
with absorbable sutures (Figures 4(a) and 4(b)). In G2, 2mL
of ABS was dropped to the amputated renal margin steadily
until bleeding stopped (Figures 4(c) and 4(d)). In G3, ABS
(2mL) + Nanopeptide gel mixture (ABS Nanohemostat) was
applied onto the injured area. And in G4, only nanopeptide
gel was used to control bleeding. Other hemostatic methods
including sponges, Surgicel, electrocautery, and any other
sourceswere not used to control bleeding in the present study.
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Figure 4: (a) and (b) Traditional partial nephrectomy model with suture on resected area dissection of kidney. (c) and (d) Transection of
kidney and application of ABS.
2.2.4. Histopathological Evaluation. Light microscopic sec-
tions were reviewed by a pathologist blinded to the treatment
groups. Coronal 1 to 2mm thick slices of the kidney were
fixed in 4% formaldehyde and embedded in paraffin, and 3 to
4 𝜇m thick tissue sections were stained with hematoxylin and
eosin. Sections were examined for several parameters includ-
ing erythroid aggregation, fibrosis, calcification, inflamma-
tory cells, and siderophages. For each case, a global estimation
of parenchymal damage was done and semiquantitatively
graded on a scale in which 0 was no abnormality, and 1+, 2+,
and 3+ representedmild,moderate, and severe abnormalities,
respectively.
2.2.5. Statistical Analyses. Data analysis was performed using
IBM Statistical Package for the Social Sciences (SPSS) statis-
tics software. Continuous variables were tested for normality
by the Kolmogorov-Smirnov test. Values were presented as
median and range because all numeric data were nonnormal-
ly distributed. Comparisons of numerical variables among
four groups were initially performed using the Kruskal-
Wallis test and Mann-Whitney 𝑈-test with the Bonferroni
correction used for post hoc analysis to compare the groups
separately. A 𝑃 value of <0.0083 (0.05/6) was deemed statis-
tically significant in multiple comparisons. The percentages
of histopathological features between study groups were
compared using the chi-squared test. A 𝑃 value of <0.05 was
considered as statistically significant.
3. Results
3.1. ABS Nanohemostat Gel Evaluation. In this work, we
synthesized a positively charged PA molecule as shown in
Figure 2. Purity of the molecule was demonstrated by using
liquid chromatography and mass spectrometry. Storage
and loss moduli measurement by oscillatory rheometry was
performed in order to characterize themechanical properties
of the gel. Storage moduli, showing stiffness of gel, were
found to be several folds higher than loss moduli, indicating
a self-supporting gel formation (Figure 5). Moreover, storage
modulus value was comparable to control gel formed by
elevating pH of PA solution. Circular dichroism spectroscopy
was used to investigate the secondary structure of the PA
and Ankaferd mixture. Characteristic 𝛽-sheet formation was
observed in PA-Ankaferd solution, which was similar to PA
solution at high pH. Morphology of the gel was examined
by using SEM which showed nanofibrous network structure
similar to PA gels reported before and PA samples at high pH.
The pH 10 solutions for PA molecule were studied to analyze
the peptide gels alone.ThePAmolecules were dissolved at pH
7, and they self-assembled into nanofibers forming gels upon
addition of Ankaferd solution or by increasing the pH to 10.
3.2. Evaluation of the Study Groups. Left lower pole PN was
surgically performed successfully to each rat in all groups.
The kidney size and shapes were similar. Likewise, the
size of the resected area was standardized for groups. The
same surgical equipments were used, and Rommel clamps
succeeded the warm ischemia during all surgical procedures.
3.3. Perioperative and Postoperative Findings. Mean ± SD
WITs were 232.8±56.3, 65.6±11.4, 75.5±17.2, and 58.1±17.6
seconds in G1 to G4, respectively. A significant difference was
detected betweenG1 andG2, 3, and 4, while no difference was
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Figure 5: Comparison of mechanical character of PA-Ankaferd gel
with PA gel formed at pH 10 by using oscillatory rheology.
observed among the three groups; G1, G2, and G3 (Table 1).
In G1, renal parenchyma injury that caused the longer WIT
and repaired with primary suture was present in one rat. In
G4, more amount of Nanopeptide agent was used to stop
the bleeding in one rat following the warm ischemia. Apart
from these two cases, no complication was observed during
the operations. Application of the ABS Nanohemostat on the
resected areawas shown in Figure 6.Hemostasis was detected
macroscopically in all rats.
3.4. Histopathological Evaluation after Scarification. All rats
were sacrificed at the first month following the surgery. Each
specimenwas protected in formalin solution. Fibrosiswas not
different among the groups (𝑃 > 0.05), while inflammation
was detected to be significantly different in G3 and G4 (𝑃 =
0.04). Erythrocyte aggregation, especially in glomerular field
(Figure 7), was confirmed to be significantly higher in G3
(ABS Nanohemostat) compared with the other groups (𝑃 =
0.03). Hemosiderin was also detected in G3; however, no
significant difference was detected among the groups. In
G4, bleeding and congestionwithout erythrocyte aggregation
were confirmed with significant calcification (𝑃 < 0.001)
(Figure 8). Table 2 shows the histopathological features of the
study groups. We confirmed the significant demonstrative
aggregation of red blood cells in ABS Nanohemostat group
as shown in ABS group. Giant cell reaction, thyroidization,
fibroblast activation, and microvascular proliferation were
not detected.
4. Discussion
In this study, we revealed that PA-Ankaferd gel mixture (ABS
Nanohemostat) is effective as traditional Ankaferd hemostat.
Table 1: Comparison of warm ischemia time (WIT) and amount of
bleeding (AOB) in study groups.
WIT (sec) AOB (cm2)
Group 1 (𝑛 = 6) 232.8 ± 56.3 7.3 ± 3.3
Group 2 (𝑛 = 6) 65.6 ± 11.4 5.7 ± 2.3
Group 3 (𝑛 = 6) 75.5 ± 17.2 5.2 ± 3.2
Group 4 (𝑛 = 6) 58.1 ± 17.6 16.4 ± 7.7
𝑃 0.003∗ 0.035∗∗
∗G1 versus G2 𝑃 = 0.0002; G1 versus G3 𝑃 = 0.002; G1 versus G4 𝑃 = 0.002;
G2 versus G3 𝑃 = 0.31; G2 versus G4 𝑃 = 0.699; G3 versus G4 𝑃 = 0.24.
∗∗G1 versus G2 𝑃 = 0.48; G1 versus G3 𝑃 = 0.39; G1 versus G4 𝑃 = 0.035;
G2 versus G3 𝑃 = 0.69; G2 versus G4 𝑃 = 0.015; G3 versus G4 𝑃 = 0.015.
Moreover, this unique nanomedicine proves itself as an effect-
ive and easily applicable alternative hemostaticmethodwhich
can successfully be used even in complicated hemorrhagic
situations such as aggressive surgical tissue bleeding due to
PN.
Several hemostatic agents are preferred to control exter-
nal and internal bleedings; yet, commercially available prod-
ucts are not sufficiently effective or fast acting to achieve
hemostasis in extreme occasions. Ankaferd hemostat is a
topical hemostatic agent of plant origin, including molecules
with high density of negative and positive charges, and is
proven to work as an efficient hemostatic agent [14–16].
Controlled clinical trials indicated the safety and efficacy of
topical Ankaferd hemostat in distinct clinical backgrounds
[19, 25–31]. In this work, we aimed to assemble a nanostruc-
tured scaffold material with hemostatic activity in the PA and
Ankaferd gel formed upon mixing soluble PA molecule with
Ankaferd solution (ABS Nanohemostat). Thus, we hypothe-
sized that, while reducing blood loss, nanofiber network will
serve as a scaffold for infiltrating cells to wound area, and
eventually tissue regeneration rate will be enhanced.
Sustaining hemostasis in clinical hemorrhages is a chal-
lenging task and requires extensive effort to stabilize trau-
matic and surgical injuries. Our experimental animal model
is therefore clinically relevant since bleeding is one of the
most importantmajor complications leading to themorbidity
and even mortality during PN for renal masses. Providing
hemostasis following the renal mass excision is the most
important step of PN [32], and various hemostatic agents
were used to stop bleeding during this operation [33–35].
Although the complication rates including bleeding are
slightly higher than those of open radical nephrectomy,
the advantage of renal preservation is more evident [32].
Likewise, laparoscopic PN, including hilar control, suture
repair of the collecting system, suture ligation of blood
vessels, and capsular closure, is also a valuable urological
intervention. Bleeding and ischemic renal damage due to
warm ischemia period are the most important complications
following surgery. In order to decreaseWIT and PNT, various
tissue sealant and haemostatic agents have been developed to
replace tissue suturing. Several agents have been investigated
for their hemostatic potential in managing vascular injury
and many have also been evaluated for their efficacy on
repairing the collecting system injury. In our results, ABS
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Figure 6: (a) and (b) Application of the ABS Nanohemostat on the resected area.
(a) (b)
(c) (d)
Figure 7: Erythrocyte aggregation in glomerular field and interstitium in ABS Nanohemostat group (20–40 xHE).
and ABS Nanohemostat applications onto the transected
kidney area provided active hemostasis in PN with signif-
icant decrease in WITs and PNTs, comparable with suture
group. With more application number of ABS products,
active hemostasis was also observed without hilar occlusion.
However, the absence of urinoma in the groups applied with
ABS may reveal the effect of ABS on collecting system repair
following one month. These favorable findings lead to the
active hemostasis and regular healing of transected kidney
without adherence and urinoma around the kidney [32]. In
our studies, we demonstrated foreign material reaction in
conventional PN model but not observed in the ABS groups.
The immunogenicity of the hemostatic molecules was out
of this present study. However, it could be speculated that
the topical ABS administration onto the sutured line might
prevent foreign biological reactions (FBRs) against the suture
by the way of affecting biological pathways.The anti-infective
effects [36–38] of ABS represent a putative biological mode of
action on the hypothetical FBR.
The hemostatic effect of local ABS application in a patient
who underwent an open PN has already been shown [34].
ABS was successfully applied to stop bleeding without sutur-
ing the renal parenchyma, which provided active hemostasis
in PN on the transected kidney area [24]. The surgical and
histopathological findings about PN in the present trial and
our previous research [32] suggested similar results regarding
the renal tissue effects of ABS.Moreover, nanotechnologically
generated chimeric ABS Nanohemostat was observed to
increase the duration of the contact of Ankaferd hemostatic
agent with the bleeding area during PN via the controlled
targeted release of the topical hemostatic agent to the tissue.
Controlled clinical studies conducted to evaluate the
effectiveness of ABS in distinct states of bleeding disorders
documented the safety and efficacy of traditional Ankaferd
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Figure 8: Bleeding and congestion without erythrocyte aggregation with significant calcification in Nanopeptide group (10 xHE).
Table 2: Histopathological features of study groups.
Parameters Group 1 (%) Group 2 (%) Group 3 (%) Group 4 (%) 𝑃
Presence
Fibrosis 0 1 (16.6) 3 (50) 2 (33.2) NS
Inflammation 0 1 (16.6) 4 (66.7) 4 (66.7) 0.048∗
Erythroid aggregation 2 (33.2) 1 (16.6) 5 (83.3) 5 (83.3) 0.036∗
Hemosiderin 2 (33.2) 2 (33.2) 5 (83.3) 4 (66.7) NS
Calcification 0 0 6 (100) 5 (83.3) <0.001∗
Overall (𝑛) 6 (100) 6 (100) 6 (100) 6 (100)
NS: not significant.
∗Significant difference was found between G1 and G2 versus G3 versus G4.
hemostat in comparison to conventional antihemorrhagic
medications. The first randomized controlled clinical study
was reported by Teker et al. [39] in 49 patients with anterior
epistaxis. In this study, patients were randomly grouped to
receive the hemostasis technique by means of either ABS
wet tampon or phenylephrine impregnated gauze tampon for
anterior epistaxis control. ABS successfully treated all bleed-
ing intensity with one application (for 5m). ABS patients
experienced fewer rebleeding rates within 7 days compared to
phenylephrine patients (8.3 versus 20%,𝑃 < 0.05). In patients
to whom ABS was applied, significant differences in effective
control of anterior epistaxis were observed compared to
phenylephrine [31]. Similarly, another clinical trial has also
demonstrated the effectiveness of ABS in children undergo-
ing tonsillectomy [30]. In this prospective controlled study,
the success of ABS and the traditional knot-tie approach
to reach hemostasis for patients undergoing tonsillectomy
was evaluated. Forty-seven consecutive patients undergoing
cold knife dissection tonsillectomy were studied, in all of
whomABS wet tampon was used for right side tonsil hemor-
rhage and knot-tie technique for left side tonsil hemorrhage.
The ABS side was reported to have shorter hemostasis time
after tonsil removal than the knot-tie side (3.19 ± 0.74min
versus 7.29 ± 2.33min, 𝑃 < 0.01) and less blood loss (1.57 ±
2.26mL versus 14.04 ± 7.23mL, 𝑃 < 0.01). The author
concluded that ABS is not only safe and efficient, but also
it decreases intraoperative bleeding and reduces operating
time compared to the traditional hemostasis methods after
cold knife dissection tonsillectomy [30]. The effectiveness of
ABS in cancer patients was also reported in a study by Al
et al. [25]. Sixty-nine cancer patients that were admitted for
port insertion to a university hospital were randomized either
to take a wet compress form of ABS or regular dry sterile
sponges to stop the bleeding that occurs during the clinically
indicated vascular port insertion. The average time needed
to stop the bleeding was 32.97 ± 29.9 s for ABS group and
123.75 ± 47.5 s for dry sponge group. ABS was proven to
stop local bleeding in a shorter time, with a lower recurrence
rate in comparison with the sterile sponge [25]. Additional
clinical studies about antihemorrhagic efficacy of ABS on the
bleeding due to adenoidectomy, [28, 40] the surgical bleeding
of thyroidectomy, [41] gastrointestinal bleedings [14, 29], and
dental bleedings [27] were performed with similar beneficial
outcomes. Our promising experimental results about ABS
Nanohemostat in this study cast novel studies to search clin-
ically measurable end-points regarding the hemostatic effi-
ciency of this unique chimeric nanomedicine. The findings
of our present study represent a starting point to investigate
clinical antihemorrhagic effects of ABS Nanohemostat.
The ability of ABS to induce formation of a protein net-
work not only makes it an effective hemostatic agent, but also
confers anti-infective, antineoplastic, and healing modulator
properties to the extract [14–16]. Those pleiotropic effects
were ascribed to the ABS-induced alterations in apoptosis,
angiogenesis, cellular proliferation, and cellular dynamics [4–
6]. In previous investigations, histopathological examination
of the damaged vascular structures revealedABS-induced red
blood cell aggregates supporting the hypothesis that ABS-
induced formation of the protein network with vital ery-
throid aggregation covers the entire physiological hemostatic
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process [42, 43]. We have observed the same structures in
the kidney tissue in the present study. In the current study,
ABS Nanohemostat has led to a more pronounced erythroid
aggregation at the tissue level in comparison to the tradi-
tional Ankaferd hemostat.However, clinical antihemorrhagic
efficiency of Ankaferd solution seems to be superior to the
chimeric Ankaferd Nanohemostat.
5. Conclusions
In summary, ABS Nanohemostat has comparable hemostatic
efficacy to the traditional Ankaferd hemostat in the PN
experimental model. ABS Nanohemostat-induced erythroid
aggregation is prominent at the kidney tissue level. These
observations prompt the design of future experimental and
clinical studies focusing on the antibleeding and vascular
repair effects of this novel hemostatic nanomedicine. The
production of ABS Nanohemostat in gel formation is also
important for using the hemostatic material during the
laparoscopic urologic surgery. The steady scaffold onto the
resected area with ABS Nanohemostat predicts the intracor-
poreal use of ABS hemostat as a promising agent. Likewise,
future controlled studies are needed to shed further light on
the expanding spectrum of the effects of ABS compounds in
hemostasis and related areas.
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oǧlu, “First clinical experience of Ankaferd Blood Stopper as a
hemostatic agent in partial nephrectomy,” Kaohsiung Journal of
Medical Sciences, vol. 26, no. 9, pp. 493–495, 2010.
[35] E.Huri, T. Akgul,O. Yucel et al., “The second step in vitro trial of
Ankaferd Blood Stopper: comparisonwith the other hemostatic
agents, glubran 2, floseal and celox,” Journal of Endourology, vol.
23, pp. A189–A189, 2009.
[36] N. Akkoc, M. Akcelik, I. C. Haznedaroglu et al., “In vitro anti-
bacterial activities of Ankaferdmedicinal plant extract,”Türkiye
Klinikleri, vol. 29, pp. 410–415, 2009.
[37] N. Tasdelen Fisgin, Y. Tanriverdi Cayci, A. Y. Coban et al., “Anti-
microbial activity of plant extract Ankaferd Blood Stopper,” Fit-
oterapia, vol. 80, no. 1, pp. 48–50, 2009.
[38] Z. Saribas, B. Sener, I. C. Haznedaroglu, G. Hascelik, S. Kirazli,
and H. Goker, “Antimicrobial activity of Ankaferd Blood Stop-
per against nosocomial bacterial pathogens,” Central European
Journal of Medicine, vol. 5, no. 2, pp. 198–202, 2010.
[39] A. M. Teker, A. Y. Korkut, V. Kahya, and O. Gedikli, “Prospec-
tive, randomized, controlled clinical trial of Ankaferd Blood
Stopper in patients with acute anterior epistaxis,” European
Archives of Oto-Rhino-Laryngology, vol. 267, no. 9, pp. 1377–1381,
2010.
[40] H. Yasar and H. Ozkul, “Haemostatic effect of Ankaferd Blood
Stopper (r) seen during adenoidectomy,”The African Journal of
Traditional, Complementary and Alternative Medicines, vol. 8,
pp. 444–446, 2011.
[41] M. Guler, G. Maralcan, S. Kul et al., “The efficacy of Ankaferd
Blood Stopper for the management of bleeding following total
thyroidectomy,” Journal of Investigative Surgery, vol. 24, pp. 205–
210, 2011.
[42] A. T. Ulus, N. N. Turan, S. Ozyalcin et al., “Surgical and histo-
pathological effects of topical Ankaferd (R) hemostat on major
arterial vessel injury related to elevated intra-arterial blood
pressure,” Turkish Journal of Hematology, vol. 28, pp. 206–212,
2011.
[43] O. Kandemir, M. Buyukates, N. O. Kandemir et al., “Dem-
onstration of the histopathological and immunohistochemical
effects of a novel hemostatic agent, Ankaferd Blood Stopper,
on vascular tissue in a rat aortic bleeding model,” Journal of
Cardiothoracic Surgery, vol. 5, no. 1, article 110, 2010.






















































Materials Science and Engineering
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Smart Materials 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Metallurgy
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Materials
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
N
a
no
m
a
te
ri
a
ls
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal ofNanomaterials
